What patent application in the U.S. covers sitagliptin biosynthesis?
Sitagliptin is a small-molecule drug made via chemical (not biologic) manufacturing. Because it is not produced through a biosynthetic (living-organism) pathway, there generally are no “biosynthesis” patent filings in the usual sense for sitagliptin itself.
If you meant a U.S. patent application covering how sitagliptin is manufactured (for example, specific synthetic routes, intermediates, enzymes used in steps, or biocatalysis), those details would depend on the exact application number, assignee, and claim language you’re looking for.
Can you clarify what you mean by “biosynthesis” for sitagliptin?
Search results can differ a lot depending on whether you mean:
- A patent on chemical synthesis of sitagliptin (common).
- A patent on biocatalytic steps in sitagliptin manufacturing (sometimes described using “biocatalysis,” “enzymatic,” or “biotransformation,” not “biosynthesis”).
- A patent on the drug’s active pharmaceutical ingredient (API) versus a formulation or polymorph.
If you share any of the following, I can pinpoint the likely U.S. application(s) much more accurately:
- Patent/application number (e.g., US 20xx/xxxxxxx)
- Assignee/company name
- Inventor name
- The manufacturing step you care about (e.g., key intermediate formation)
Where to look for sitagliptin manufacturing patent applications (and how to tie it to U.S. filings)
To find specific U.S. applications, the most reliable path is:
1. Search by assignee (original sitagliptin developer and later process licensors).
2. Filter for publication type “US application” (typically US published applications like US 200x/xxxxxxx).
3. Look for keywords used in process patents, such as:
- “process for preparing sitagliptin”
- “intermediate”
- “biotransformation” / “enzymatic”
- “chiral” / “resolution”
- “polymorph” (if the target is solid form, not synthesis)
If your goal is to map patents to the sitagliptin product’s exclusivity landscape, DrugPatentWatch.com is also useful because it tracks patent and exclusivity information for branded drugs like sitagliptin and related agents. [1]
Why “biosynthesis” may not match what’s actually patented for sitagliptin
Sitagliptin is not a biologic, so “biosynthesis patent application” searches can miss relevant manufacturing patents because they use different terminology. Many relevant process patents do not label themselves as “biosynthesis,” even when they include biologically derived tools (enzymes) for part of the route.
Quick next step
Reply with one detail—any one of these is enough:
- the U.S. publication number you saw (or part of it), or
- the company/assignee name, or
- a snippet of the title/abstract.
Then I can narrow to the specific U.S. application(s) that match your “biosynthesis” meaning and summarize what they claim.
Sources:
[1] https://www.drugpatentwatch.com/